SEC Stock Data Quick Answer Akebia Therapeutics, Inc. reported R&D Expense of $62.36 million for fiscal year 2025. Akebia Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $62.36M +65.6% 2024 $37.65M -40.3% 2023 $63.08M -51.5% 2022 $129.99M -12.1% 2021 $147.85M -32.3% 2020 $218.49M -32.4% 2019 $322.97M +11.0% 2018 $291.01M +26.0% 2017 $230.89M … Read more
Quick Answer Akebia Therapeutics, Inc. reported Stockholders Equity of $32.61 million for fiscal year 2025. Akebia Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $32.61M +166.3% 2024 -$49.19M -60.8% 2023 -$30.58M -684.8% 2022 $5.23M -92.9% 2021 $74.01M -70.1% 2020 $247.62M -37.3% 2019 $394.76M -37.9% 2018 $635.93M +418.8% 2017 $122.57M … Read more
Quick Answer Akebia Therapeutics, Inc. reported Long-Term Debt of $48.25 million for fiscal year 2025. Akebia Therapeutics, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $48.25M +24.7% 2024 $38.69M +125.2% 2023 $17.18M -49.6% 2022 $34.08M — 2021 $0.00 -100.0% 2020 $96.38M +27.1% 2019 $75.81M — Quarterly Long-Term Debt Quarter Ending … Read more
Quick Answer Akebia Therapeutics, Inc. reported Cash and Equivalents of $184.84 million for fiscal year 2025. Akebia Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $184.84M +256.4% 2024 $51.87M +20.8% 2023 $42.92M -52.6% 2022 $90.47M -39.6% 2021 $149.80M -34.5% 2020 $228.70M +55.1% 2019 $147.45M +40.9% 2018 $104.64M … Read more
Quick Answer Akebia Therapeutics, Inc. reported Total Assets of $376.56 million for fiscal year 2025. Akebia Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $376.56M +70.6% 2024 $220.67M -8.7% 2023 $241.70M -32.1% 2022 $356.05M -32.3% 2021 $525.55M -18.4% 2020 $644.14M -16.5% 2019 $771.20M -22.6% 2018 $996.54M +173.6% 2017 $364.25M … Read more
Quick Answer Akebia Therapeutics, Inc. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2025. Akebia Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.02 +93.9% 2024 -$0.33 -17.9% 2023 -$0.28 +46.2% 2022 -$0.52 +69.4% 2021 -$1.70 +38.6% 2020 -$2.77 -17.4% 2019 -$2.36 — Quarterly Diluted EPS … Read more
Quick Answer Akebia Therapeutics, Inc. reported Net Income of -$5.34 million for fiscal year 2025. Akebia Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$5.34M +92.3% 2024 -$69.41M -33.7% 2023 -$51.92M +44.9% 2022 -$94.23M +66.7% 2021 -$282.84M +26.2% 2020 -$383.46M -37.1% 2019 -$279.66M -94.8% 2018 -$143.59M -94.9% 2017 -$73.67M … Read more
Quick Answer Akebia Therapeutics, Inc. reported Revenue (ASC 606) of $236.20 million for fiscal year 2025. Akebia Therapeutics, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $236.20M +47.5% 2024 $160.18M -17.7% 2023 $194.62M -33.5% 2022 $292.48M +36.9% 2021 $213.58M -27.7% 2020 $295.31M -11.8% 2019 $335.00M +61.3% 2018 $207.74M … Read more
Quick Answer Akebia Therapeutics, Inc. reported Total Revenue of $236.20 million for fiscal year 2025. Akebia Therapeutics, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $236.20M +47.5% 2024 $160.18M -17.7% 2023 $194.62M -33.5% 2022 $292.48M +36.9% 2021 $213.58M -27.7% 2020 $295.31M -11.8% 2019 $335.00M +61.3% 2018 $207.74M +14.6% 2017 $181.23M … Read more
Quick Answer Akebia Therapeutics, Inc. reported Total Revenue of $236.20 million for fiscal year 2025. Akebia Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $236.20M+47.5% $160.18M-17.7% $194.62M-33.5% $292.48M+36.9% $213.58M-27.7% $295.31M-11.8% Revenue (ASC 606) $236.20M+47.5% $160.18M-17.7% $194.62M-33.5% $292.48M+36.9% $213.58M-27.7% $295.31M-11.8% Net Income -$5.34M+92.3% -$69.41M-33.7% -$51.92M+44.9% -$94.23M+66.7% -$282.84M+26.2% -$383.46M-37.1% … Read more